BioEclipse Therapeutics™ is a clinical-stage oncology company that uses its proprietary technology to develop the next generation of immuno-oncology therapeutics. Foundationally, we have harnessed a refined understanding of the human immune system, gaining insights into the reasons the body’s defense system so often turns a blind eye to the presence of cancerous cells and tumors. In response, BioEclipse Therapeutics™ pairs activated immune cells with an adapted oncolytic virus that selectively infects and kills malignant cells. The result of this combination is a multi-mechanistic, targeted treatment that we believe will not only eradicate cancer cells, but also protect the patient from relapse and recurrence, through a durable immune response that prevents the development of new cancers, even in the face of new challenges from disease.
Location: United States, California, Mountain View
Employees: 1-10
Total raised: $15.7M
Founded date: 2017
Investors 4
| Date | Name | Website |
| - | Tsingyuan ... | tsingyuan.... |
| - | Revelis Ca... | reveliscap... |
| - | Plum Alley... | plumalley.... |
| - | Foothill V... | foothill.v... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 25.04.2022 | Grant | $8M | - |
| 24.06.2019 | Series A | $7.7M | - |
Mentions in press and media 6
| Date | Title | Description |
| 05.03.2021 | BioEclipse Therapeutics Announces First Patient Dosed in Phase 1 Dose-Escalation Clinical Trial of CRX100 in Refractory Solid Tumors | |
| 01.07.2019 | BioEclipse Therapeutics Raises $7.7 Million To Conduct Human Trials Of Its Intravenous Tumor-Targeted Combination Immunotherapy | BioEclipse Therapeutics, a private clinical-stage biopharmaceutical company, announced it raised $7.7 million in Series A-1 financing round Private clinical-stage biopharmaceutical company BioEclipse Therapeutics is known for developing hig... |
| 25.06.2019 | BioEclipse Therapeutics Inks $7.7M in Series A-1 | SOUTH SAN FRANCISCO, CA, BioEclipse Therapeutics announced that it has raised $7.7 million in its Series A-1 financing round. >> Click here for more funding data on BioEclipse Therapeutics >> To export BioEclipse Therapeutic... |
| 25.06.2019 | Longtime Analyst Mark Mahaney: ‘The Bar Is Higher In the Public Markets:’ Term Sheet | ‘THE BAR IS HIGHER IN THE PUBLIC MARKETS’ We’re already halfway through the year, and a number of tech startups finally made their public market debut — Uber, Lyft, Zoom, Pinterest, PagerDuty, Beyond Meat, CrowdStrike, and most recently, Sl... |
| 24.06.2019 | Top tech startup news for today, Monday, June 24, 2019 | Below are some of the top tech startup news for today, Monday, June 24, 2019. Bitcoin soars above $11,000 for the first time in 15 months, now up 170% for the year. Bitcoin rally rages on with no signs of slow down. Investors don’t seem to... |
| 24.06.2019 | BioEclipse Therapeutics Raises $7.7M in Series A-1 Financing | BioEclipse Therapeutics, a South San Francisco-based clinical-stage biopharmaceutical company, raised $7.7m in Series A-1 financing. The round, which brought total funding raised to date to $9.3m, was led by Revelis Capital Group, with part... |